Oral and intramuscular administration of vitamin D in patients with nonalcoholic fatty liver

Comparison of serum level of vitamin D in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) after administration of Oral & Intramuscular Vit D

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190701044062N2

Enrollment

Registered

2020-01-13

Start date

2020-01-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group : Patients in this group will receive injection muscle vitamin D as 300,000,000 units every month for two month. Intervention 2: Control group: In this group, patien

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult Patients Over 18 Years With Non-alcoholic Fatty Liver Disease (NAFLD) Based on Diagnosis of Gastroenterologist Osteatogenic drugs vitamin D deficiency (25-hydroxyvitamin D level less than 20 ng / ml), and informed patient consent to participate in the study informed patient consent to participate in the study

Exclusion criteria

Exclusion criteria: Alcohol consumption hereditary history osteogenic drugs hepatitis metabolic diseases Recent consumption of vitamin D

Design outcomes

Primary

Measure	Time frame
Vitamin D levels in both groups will be measured at baseline. One group of patients will be treated with oral vitamin D (pear vitamin D) at 50,000 units weekly for one month and then 50,000 units monthly for one month. In the second group, patients will receive vitamin D of 300,000 units two months apart. The level of 25-hydroxyvitamin D in both groups will be re-measured 2 months after the start of treatment. The primary outcome of the present study was the level of 25-hydroxyvitamin D levels 3 months after initiation of vitamin D treatment. Timepoint: Vitamin D levels in both groups will be measured at baseline. It will be re-measured 2 months after the start of treatment. Method of measurement: blood test.	—

Measure

Time frame

Vitamin D levels in both groups will be measured at baseline. One group of patients will be treated with oral vitamin D (pear vitamin D) at 50,000 units weekly for one month and then 50,000 units monthly for one month. In the second group, patients will receive vitamin D of 300,000 units two months apart. The level of 25-hydroxyvitamin D in both groups will be re-measured 2 months after the start of treatment. The primary outcome of the present study was the level of 25-hydroxyvitamin D levels 3 months after initiation of vitamin D treatment. Timepoint: Vitamin D levels in both groups will be measured at baseline. It will be re-measured 2 months after the start of treatment. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManouchehr Khoshbaten

Tabriz University of Medical Sciences

mkhoshbaten@yahoo.com+98 41 3337 2088

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026